Human Neonatal Rotavirus Vaccine (RV3-BB) to Target Rotavirus from Birth.

Julie E BinesJarir At ThobariCahya Dewi SatriaAmanda HandleyEmma WattsDaniel CowleyHera NirwatiJames AcklandJane StandishFrances JusticeGabrielle ByarsKatherine J LeeGraeme L BarnesNovilia S BachtiarAjeng Viska IcanerviliaKaren BonifaceNada Bogdanovic-SakranDaniel PavlicRuth F BishopCarl D KirkwoodJim P ButteryYati Soenarto

Published in: The New England journal of medicine (2018)

RV3-BB was efficacious in preventing severe rotavirus gastroenteritis when administered according to a neonatal or an infant schedule in Indonesia. (Funded by the Bill and Melinda Gates Foundation and others; Australian New Zealand Clinical Trials Registry number, ACTRN12612001282875 .).

Keyphrases

mycobacterium tuberculosis
clinical trial
growth factor
endothelial cells
recombinant human
early onset
induced pluripotent stem cells
pluripotent stem cells
gestational age
pregnant women
study protocol
phase iii